Title: Aarkstore - Lonsurf (Colorectal Cancer) - Forecast and Market Analysis to 2023
1Aarkstore - Lonsurf (Colorectal Cancer)
- Forecast and Market Analysis to 2023
Category Healthcare
2Summary
Colorectal cancer (CRC) is the second leading
cause of mortality among cancer patients in the
world and is the third most diagnosed cancer
globally, and thus represents a huge burden on
healthcare systems. This report focuses on the
current treatment landscape, unmet needs, current
pipeline, and commercial opportunities in the
colorectal cancer market, with coverage of
multiple settings of the disease including
neoadjuvant/adjuvant, first-, second-, third-line
KRAS wild-type and mutation-positive, and
fourth-line metastatic. Taiho Pharmaceuticals
Lonsurf (TAS-102) is an oral nucleoside antitumor
drug which launched in 2014 for the treatment of
chemotherapy-refractive metastatic CRC in Japan.
In May 2014, Taiho Pharmaceutical announced that
the Phase III RECOURSE trial met its primary
outcome of OS and that the company is preparing
for regulatory submission in the US and Europe.
Browse Complete Report http//www.aarkstore.com
/healthcare/87979/lonsurf-colorectal-cancer-foreca
st-and-market-analysis-to-2023
3Scope
- - Overview of Colorectal Cancer, including
epidemiology, etiology, symptoms, diagnosis,
pathology and treatment guidelines as well as an
overview on the competitive landscape. - - Detailed information on Lonsurf including
product description, safety and efficacy profiles
as well as a SWOT analysis. - - Sales forecast for Lonsurf for the top eight
countries from 2013 to 2023. - - Sales information covered for the US, France,
Germany, Italy, Spain, the UK, Japan and China.
4Reasons to buy
- Understand and capitalize by identifying products
that are most likely to ensure a robust return - Stay ahead of the competition by understanding
the changing competitive landscape for Colorectal
Cancer - Effectively plan your MA and partnership
strategies by identifying drugs with the most
promising sales potential - - Make more informed business decisions from
insightful and in-depth analysis of Lonsurf
performance
5Table of Content
- 1.1 List of Tables 7
- 2 Introduction 8
- 2.1 Catalyst 8
- 2.2 Related Reports 9
- 2.3 Upcoming Related Reports 10
- 3 Disease Overview 11
- 3.1 Etiology and Pathophysiology 11
- 3.1.1 Etiology 11
- 3.1.2 Pathophysiology 13
- 3.2 Clinical Staging 14
- 3.3 Symptoms 15
6List of Tables
- Table 1 TNM and Staging Classification System
for CRC 15 - Table 2 Symptoms of Colorectal Cancer 16
- Table 3 Treatment Guidelines for CRC 21
- Table 4 Most-Prescribed Neoadjuvant/Adjuvant
Regimens for Early-Stage CRC in the Global
Markets, 2013 22 - Table 5 Most Prescribed Targeted Therapies for
Metastatic CRC by Segment in the Global Markets,
2013 23 - Table 6 Leading Treatments for CRC, 2014 32
- Table 7 Product Profile - Lonsurf 35
- Table 8 Lonsurf SWOT Analysis, 2014 37
- Table 9 Global Sales Forecasts (m) for Lonsurf
(TAS-102), 2013-2023 38 - Table 10 Average Body Weight and Surface Area
Across the 8MM 49 - Table 11 High-Prescribing Physicians (non-KOLs)
Surveyed, By Country 53 -
7Related reports
- OpportunityAnalyzer Gout - Opportunity Analysis
and Forecast to 2018 - Linzess (Irritable Bowel Syndrome) - Forecast and
Market Analysis to 2023 - North American Nerve Repair Regeneration Market
by Type (Neurostimulation, Nerve Conduits, Nerve
Protectors, Nerve Wraps, Nerve Connectors), by
Procedure (Direct Nerve Repair, Nerve Grafting,
Neuromodulation Surgery, Stem Cell Therapy)
-Forecast to 2019 - Asian Stationary Cycle Market by Product
(Recumbent Stationary Cycle, Upright Stationary
Cycle), by Pricing of Equipment ( Premium
Equipment, Budget Equipment), by End User
(Vertical Markets, Health Clubs, Home Fitness) -
Forecasts to 2019 - Oncology Information System Market by Software
(Patient Information System TPS),
Professional Service), Application (Medical,
Radiation, Surgical Oncology), End User
(Hospital, Government Institution, Research
Center) - Global Forecasts to 2019
8- Lonsurf (Colorectal Cancer)
- Published Nov 2014 57 Pages
- Colorectal cancer (CRC) is the second leading
cause of mortality among cancer patients in the
world and is the third most diagnosed cancer
globally, and thus represents a huge burden on
healthcare systems. - Price
Formats Price
PDF 3495
Site License 6990
Enterprise Wide License 10485
9Contact Us
Office Office No. - 809, 8th Floor,B-Wing,
Mahaavir Icon, Plot No.- 89 90,
Sector-15,CBD-Belapur, Navi Mumbai
400614, Maharashtra, India. Telefax No 91 22
4127 6660 24/7 Online Support 91
9987295242 General Inquiries 91 - 22 2756 4953
- You Can Visit http//www.aarkstore.com
- OR Mail us at contact_at_aarkstore.com
- Blog
- http//www.aarkstore.com/blog/
- Conference
- http//conference.aarkstore.com/
- News
- http//www.aarkstore.com/news